Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.48 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17413289 | 0.90 | RAB9A (0.58) | RAB9ASMN1; SMN2MAPTTP53NPC1 | |
| SCHEMBL25999795 | 0.89 | RAB9A (0.56) | RAB9ASMN1; SMN2MAPTTP53NPC1 | |
| SCHEMBL16147472 | 0.86 | NR1H4 (0.52) | RAB9ASMN1; SMN2MAPTNR5A2NR5A1 | |
| SCHEMBL20305839 | 0.86 | NR5A2 (0.46) | RAB9ASMN1; SMN2MAPTNR5A2NR5A1 | |
| SCHEMBL28772807 | 0.84 | RAB9A (0.46) | RAB9ASMN1; SMN2MAPTNR5A2NR5A1 | |
| SCHEMBL16147357 | 0.84 | ALDH1A1 (0.51) | RAB9ASMN1; SMN2MAPTNR5A2NR5A1 | |
| SCHEMBL30554594 | 0.83 | MAPT (0.57) | RAB9ASMN1; SMN2MAPTTP53NPC1 | |
| SCHEMBL3166099 | 0.83 | MAPT (0.57) | RAB9ASMN1; SMN2MAPTTP53NPC1 | |
| SCHEMBL20305922 | 0.82 | RAB9A (0.58) | RAB9ASMN1; SMN2MAPTTP53NPC1 | |
| SCHEMBL2787082 | 0.81 | MEN1 (0.46) | NR5A2NR5A1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | RAB9A 3749/4885SMN1; SMN2 2914/4885MAPT 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.